MENLO PARK, Calif., March 19, 2026 /PRNewswire/ -- Endovascular Engineering, Inc. ("E2") today announced that two abstracts related to the ENGULF study and the Hēlo® Platform have been accepted as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results